Literature DB >> 18248785

Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.

Edenir Inêz Palmero1, Lavínia Schüler-Faccini, Maira Caleffi, Maria Isabel Waddington Achatz, Magali Olivier, Ghyslaine Martel-Planche, Virginie Marcel, Ernestina Aguiar, Juliana Giacomazzi, Ingrid Petroni Ewald, Roberto Giugliani, Pierre Hainaut, Patricia Ashton-Prolla.   

Abstract

Germline TP53 mutations predispose to a rare familial cancer syndrome, the Li-Fraumeni Syndrome (LFS), characterized by the early onset of multiple cancers including childhood adrenocortical carcinomas, sarcomas and brain tumors, and breast and colon cancer in young adults. An identical germline mutation at codon 337 in TP53 (R337H) has been shown to be causally related to an increased risk of multiple cancers in unrelated subjects with familial cancer risk in Southern Brazil. Here we have assessed the prevalence of R337H in 750 healthy women participating in a community-based breast cancer screening program in the area of Porto Alegre. The mutant was detected in two participants (0.3%) who were fourth-degree relatives and reported a familial history of cancer at multiple sites that did not match classical criteria for LFS and its variants. Testing in additional family members detected the mutation in three subjects, one of whom developed breast cancer at the age of 36. These findings indicate that R337H may be a low penetrance mutant which predisposes to multiple cancers and occurs in the population of Southern Brazil at a frequency 10-20 times higher than other TP53 mutants commonly associated with LFS.

Entities:  

Mesh:

Year:  2008        PMID: 18248785     DOI: 10.1016/j.canlet.2007.10.044

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  52 in total

Review 1.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

2.  The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers.

Authors:  Mariana Fitarelli-Kiehl; Juliana Giacomazzi; Patricia Santos-Silva; Marcia Silveira Graudenz; Edenir Inez Palmero; Rodrigo Augusto Depieri Michelli; Maria Isabel Achatz; Cynthia Aparecida Bueno de Toledo Osório; Victor Evangelista de Faria Ferraz; Clarissa Gondim Picanço; Patricia Ashton-Prolla
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

Review 3.  Breast cancer in young women.

Authors:  Steven A Narod
Journal:  Nat Rev Clin Oncol       Date:  2012-06-26       Impact factor: 66.675

4.  p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.

Authors:  Gabriel S Macedo; Igor Araujo Vieira; Fernanda Salles Luiz Vianna; Barbara Alemar; Juliana Giacomazzi; Ana Paula Carneiro Brandalize; Maira Caleffi; Sahlua Miguel Volc; Henrique de Campos Reis Galvão; Edenir Inez Palmero; Maria Isabel Achatz; Patricia Ashton-Prolla
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

5.  New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer.

Authors:  D Gareth Evans; Emma R Woodward
Journal:  Fam Cancer       Date:  2021-01       Impact factor: 2.375

Review 6.  The Inherited p53 Mutation in the Brazilian Population.

Authors:  Maria Isabel Achatz; Gerard P Zambetti
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

7.  Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis.

Authors:  Beng Hooi Phang; Rashidah Othman; Gaelle Bougeard; Ren Hui Chia; Thierry Frebourg; Choong Leong Tang; Peh Yean Cheah; Kanaga Sabapathy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

8.  Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population.

Authors:  Mang Xiao; Lei Zhang; Xinhua Zhu; Jun Huang; Huifen Jiang; Sunhong Hu; Yuehui Liu
Journal:  BMC Cancer       Date:  2010-04-18       Impact factor: 4.430

Review 9.  Connecting molecular pathways to hereditary cancer risk syndromes.

Authors:  Joseph R Testa; David Malkin; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

Review 10.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.